title: In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer.
abstract: BACKGROUND
  The aim of our study was to analyze the effect of taxane-based chemotherapy on tumor angiogenesis in patients with advanced epithelial ovarian cancer.
  
  
  METHODS
  Within a prospective phase II trial, 32 patients with stage IIIC and IV ovarian cancer were treated with either two or three cycles of neoadjuvant chemotherapy prior to cytoreductive surgery. Carboplatin (AUC5) and docetaxel (75 mg/m2) were administered intravenously in a 3-weekly schedule. Changes in intratumor microvessel density (MVD) were assessed with immunohistochemistry by staining pre- and posttreatment surgical tumor specimens with panendothelial, neovascular and lymphatic vessel markers.
  
  
  RESULTS
  Mean values of MVD defined by CD31, CD34, CD105 and D2-40 antibodies showed 12.3, 21.0, 2.7 and 3.1 vessels per high power field (HPF) before chemotherapy and increased after treatment to 15.3, 21.8, 4.8 and 3.6 per HPF, respectively. These changes were significant for CD31 (p = 0.04) and for CD105 (p = 0.02).
  
  
  CONCLUSIONS
  Taxane-based chemotherapy appears to promote tumor vascularization when administered every 3 weeks. A possible explanation is the secondary recovery of MVD in response to immediate cytotoxic and antiangiogenic effects of the chemotherapy. If confirmed prospectively, these findings favor shorter treatment intervals of taxane-based chemotherapy to counteract proangiogenic recovery.
authors.affiliation: Department of Gynecology and Obstetrics, Center for Integrated Oncology, Bonn University Medical Center, Germany. martin.poelcher@ukb.uni-bonn.de
authors.forename: Martin
authors.initials: M
authors.lastname: Pölcher
authors.forename: Christian
authors.initials: C
authors.lastname: Rudlowski
authors.forename: Nicolaus
authors.initials: N
authors.lastname: Friedrichs
authors.forename: Marieke
authors.initials: M
authors.lastname: Mielich
authors.forename: Tobias
authors.initials: T
authors.lastname: Höller
authors.forename: Mathias
authors.initials: M
authors.lastname: Wolfgarten
authors.forename: Kirsten
authors.initials: K
authors.lastname: Kübler
authors.forename: Reinhard
authors.initials: R
authors.lastname: Büttner
authors.forename: Walther
authors.initials: W
authors.lastname: Kuhn
authors.forename: Michael
authors.initials: M
authors.lastname: Braun
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D005858:Germany; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D055806:Microvessels / Q000187:drug effects / Q000473:pathology; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic / Q000139:chemically induced / Q000517:prevention & control*; D010051:Ovarian Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D016016:Proportional Hazards Models; D011446:Prospective Studies; D043823:Taxoids / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D043823:Taxoids; D000077143:Docetaxel; D016190:Carboplatin
references.citation: Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:183-9
references.pmid: 16515588
references.citation: Cancer Cell. 2009 Mar 3;15(3):232-9
references.pmid: 19249681
references.citation: Am J Pathol. 1995 Jul;147(1):9-19
references.pmid: 7541613
references.citation: Int J Cancer. 2003 Mar 10;104(1):121-9
references.pmid: 12532428
references.citation: Oncogene. 2001 Jun 28;20(29):3806-13
references.pmid: 11439344
references.citation: J Clin Oncol. 2004 Feb 15;22(4):686-90
references.pmid: 14966092
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5165-71
references.pmid: 18024863
references.citation: Cancer Res. 2005 Mar 15;65(6):2433-40
references.pmid: 15781659
references.citation: Blood. 1996 Jan 1;87(1):1-13
references.pmid: 8547630
references.citation: Histol Histopathol. 2009 Apr;24(4):425-35
references.pmid: 19224445
references.citation: Oncogene. 2003 Sep 29;22(42):6557-63
references.pmid: 14528280
references.citation: Expert Rev Anticancer Ther. 2004 Aug;4(4):639-47
references.pmid: 15270667
references.citation: Cancer Cell. 2008 Sep 9;14(3):263-73
references.pmid: 18772115
references.citation: Cancer Res. 1997 Jan 1;57(1):81-6
references.pmid: 8988045
references.citation: J Clin Oncol. 2008 Jan 1;26(1):76-82
references.pmid: 18165643
references.citation: Breast Cancer Res Treat. 1995;36(2):169-80
references.pmid: 8534865
references.citation: J Clin Oncol. 2003 Aug 1;21(15):2843-8
references.pmid: 12807937
references.citation: Wiad Lek. 2007;60(3-4):129-37
references.pmid: 17726864
references.citation: Cancer Lett. 1999 Apr 26;138(1-2):175-82
references.pmid: 10378790
references.citation: Int J Cancer. 1996 Jun 21;69(3):205-11
references.pmid: 8682589
references.citation: Cancer. 2001 Nov 15;92(10):2585-91
references.pmid: 11745193
references.citation: J Clin Oncol. 2001 Feb 15;19(4):1195-206
references.pmid: 11181686
references.citation: Cancer Lett. 2002 Feb 8;176(1):111-8
references.pmid: 11790460
references.citation: Lancet. 2009 Oct 17;374(9698):1331-8
references.pmid: 19767092
references.citation: Cancer Cell. 2009 Mar 3;15(3):220-31
references.pmid: 19249680
references.citation: J Clin Oncol. 2000 Jan;18(1):106-15
references.pmid: 10623700
references.citation: Nat Rev Cancer. 2006 Nov;6(11):835-45
references.pmid: 17036040
references.citation: Int J Gynecol Cancer. 2004 Sep-Oct;14(5):815-23
references.pmid: 15361189
references.citation: Ann N Y Acad Sci. 1994 Apr 18;714:165-74
references.pmid: 8017765
references.citation: Anticancer Res. 2006 Sep-Oct;26(5B):3925-32
references.pmid: 17094423
references.citation: Am J Physiol Cell Physiol. 2004 Sep;287(3):C572-9
references.pmid: 15308462
references.citation: Oncol Rep. 2009 Sep;22(3):605-13
references.pmid: 19639211
references.citation: Cancer Res. 2001 Apr 15;61(8):3369-72
references.pmid: 11309294
references.citation: Lab Invest. 2002 Sep;82(9):1255-7
references.pmid: 12218087
references.citation: N Engl J Med. 1971 Nov 18;285(21):1182-6
references.pmid: 4938153
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5180-6
references.pmid: 18024865
references.citation: Crit Rev Oncol Hematol. 2009 Feb;69(2):108-24
references.pmid: 18768327
references.citation: Mol Cancer Ther. 2002 Nov;1(13):1191-200
references.pmid: 12479700
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: Gynecol Oncol. 2009 Mar;112(3):469-74
references.pmid: 19135712
references.citation: Cancer Metastasis Rev. 2000;19(1-2):67-73
references.pmid: 11191065
references.citation: Cancer Res. 2003 Aug 1;63(15):4342-6
references.pmid: 12907602
references.citation: Clin Cancer Res. 1999 Mar;5(3):587-91
references.pmid: 10100710
references.citation: Nat Rev Cancer. 2005 Jul;5(7):516-25
references.pmid: 15965493
references.citation: Nat Rev Cancer. 2004 Jun;4(6):423-36
references.pmid: 15170445
references.citation: Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92
references.pmid: 17161157
references.citation: Cancer Res. 2007 Jan 1;67(1):281-8
references.pmid: 17210709